We are live on ! Find out more
CRMD icon

CorMedix

47 hedge funds and large institutions have $48.6M invested in CorMedix in 2019 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 8

54% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 13

40% more capital invested

Capital invested by funds: $34.8M → $48.6M (+$13.9M)

18% more funds holding

Funds holding: 4047 (+7)

7.32% more ownership

Funds ownership: 15.47%22.78% (+7.3%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

20% less call options, than puts

Call options by funds: $3.62M | Put options by funds: $4.5M

Holders
47
Holders Change
+7
Holders Change %
+17.5%
% of All Funds
1.02%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
20
Increased
13
Reduced
8
Closed
13
Calls
$3.62M
Puts
$4.5M
Net Calls
-$879K
Net Calls Change
+$2.72M

CRMD Hedge Fund Activity: Q2 2019 in Review

47 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q2 2019, worth a combined $48.6M — up 40% from $34.8M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new CRMD positions and 13 closed out — a net gain of 7 holders — while 13 added to existing stakes and 8 trimmed.

The largest buyer was BlackRock, adding an estimated $7.66M. The largest seller was EAM Investors, exiting entirely with an estimated $1.38M sold.

  • 47 institutional investors held CorMedix (CRMD) as of Q2 2019, up from 40 in Q1 2019.
  • Funds reported $48.6M of CorMedix stock for Q2 2019, up 40% quarter-over-quarter.
  • 20 funds opened new CorMedix positions in Q2 2019 and 13 closed out, a net change of +7 holders.
  • The largest CorMedix buyer in Q2 2019 was BlackRock, an estimated $7.66M added.
  • The largest CorMedix seller in Q2 2019 was EAM Investors, an estimated $1.38M sold.

Based on aggregated 13F filings for Q2 2019.